Clinical Trial

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Protocol Amendment History 4 changes
notable Trial sites reduced: 323 -> 242 locations 2026-07-21
notable Primary completion moved earlier: 2028-04 -> 2027-10 2026-07-21
minor Completion moved earlier: 2028-07 -> 2027-11 2026-07-21
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-11
Trial Details
NCT Number NCT06981078
Lead Sponsor Upstream Bio Inc.
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 666 participants
Start Date 2025-07-02
Primary Completion 2027-10 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-20